Bioluminescence imaging: Looking beyond the light

Trends in Molecular Medicine

Volumn 18, Issue 3, 2012, Pages 164-172

  Keyaerts, Marleen ^a,b   Caveliers, Vicky ^a,b   Lahoutte, Tony ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ENZYME INHIBITOR; FIREFLY LUCIFERASE; HEAT SHOCK PROTEIN;

APOPTOSIS; BIOAVAILABILITY; BIOLUMINESCENCE IMAGING; CARDIOVASCULAR FUNCTION; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE TRANSFER; HEMATOLOGICAL PARAMETERS; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; LIGHT ABSORPTION; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; OXIDATIVE STRESS; PROMOTER REGION; PROTEIN STABILITY; REPORTER GENE; REVIEW; TRANSGENIC ANIMAL;

ANIMALS; HUMANS; LUMINESCENT MEASUREMENTS; LUMINESCENT PROTEINS; MOLECULAR IMAGING;

EID: 84858070141     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.01.005     Document Type: Review

References (75)

1. Massoud T.F., Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003, 17:545-580.
2. Contag C.H., et al. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem. Photobiol. 1997, 66:523-531.
3. Lyman G.E., DeVincenzo J.P. Determination of picogram amounts of ATP using the luciferin-luciferase enzyme system. Anal. Biochem. 1967, 21:435-443.
4. Contag C.H. Functional imaging using bioluminescent markers. Molecular Imaging: Principles and Practice 2010, 118-138. People's Medical Publishing House. R.R.B. Weissleder (Ed.).
5. Edinger M., et al. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003, 101:640-648.
6. Doyle T.C., et al. In vivo bioluminescence imaging for integrated studies of infection. Cell. Microbiol. 2004, 6:303-317.
7. Koya R.C., et al. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14286-14291.
8. Reumers V., et al. Noninvasive and quantitative monitoring of adult neuronal stem cell migration in mouse brain using bioluminescence imaging. Stem Cells 2008, 26:2382-2390.
9. Blasberg R.G. Molecular imaging and cancer. Mol. Cancer Ther. 2003, 2:335-343.
10. Gross S., Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 2005, 7:5-15.
11. Rehemtulla A., et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000, 2:491-495.
12. Tchouate Gainkam L.O., et al. Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. Mol. Imaging Biol. 2011, 13:940-948.
13. Disson O., et al. Conjugated action of two species-specific invasion proteins for fetoplacental listeriosis. Nature 2008, 455:1114-1118.
14. Luker K.E., Luker G.D. Real-time bioluminescence imaging of viral pathogenesis. Methods Mol. Biol. 2009, 574:125-135.
15. Waidmann M.S., et al. Bacterial luciferase reporters: the Swiss army knife of molecular biology. Bioeng. Bugs 2011, 2:8-16.
16. Xie X., et al. Imaging of STAT3 signaling pathway during mouse embryonic stem cell differentiation. Stem Cells Dev. 2009, 18:205-214.
17. Yan Z., et al. Indexing TNF-alpha gene expression using a gene-targeted reporter cell line. BMC Biol. 2009, 7:8.
18. Brightwell G., et al. Serum-dependent and cell cycle-dependent expression from a cytomegalovirus-based mammalian expression vector. Gene 1997, 194:115-123.
19. Svensson R.U., et al. Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res. 2007, 67:10445-10454.
20. Hingorani M., et al. Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin. Cancer Res. 2008, 14:4915-4924.
21. Hundt W., et al. The effect of high intensity focused ultrasound on luciferase activity on two tumor cell lines in vitro, under the control of a CMV promoter. Ultrasonics 2009, 49:312-318.
22. Bruening W., et al. Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. Nucleic Acids Res. 1998, 26:486-489.
23. Norrman K., et al. Quantitative comparison of constitutive promoters in human ES cells. PLoS ONE 2010, 5:e12413.
24. Krishnan M., et al. Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging. FASEB J. 2006, 20:106-108.
25. Galam L., et al. High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. Bioorg. Med. Chem. 2007, 15:1939-1946.
26. Minami Y., Minami M. Hsc70/Hsp40 chaperone system mediates the Hsp90-dependent refolding of firefly luciferase. Genes Cells 1999, 4:721-729.
27. Thulasiraman V., Matts R.L. Effect of geldanamycin on the kinetics of chaperone-mediated renaturation of firefly luciferase in rabbit reticulocyte lysate. Biochemistry 1996, 35:13443-13450.
28. Czupryna J., Tsourkas A. Firefly luciferase and rluc8 exhibit differential sensitivity to oxidative stress in apoptotic cells. PLoS ONE 2011, 6:e20073.
29. Deroo B.J., Archer T.K. Proteasome inhibitors reduce luciferase and beta-galactosidase activity in tissue culture cells. J. Biol. Chem. 2002, 277:20120-20123.
30. Wu H.M., et al. Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. FEBS Lett. 2002, 526:101-105.
31. Thorne N., et al. Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem. Biol. 2010, 17:646-657.
32. Edinger M., et al. Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia 1999, 1:303-310.
33. Bhaumik S., Gambhir S.S. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:377-382.
34. Keyaerts M., et al. Plasma protein binding of luciferase substrates influences sensitivity and accuracy of bioluminescence imaging. Mol. Imaging Biol. 2011, 13:59-66.
35. Paroo Z., et al. Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol. Imaging 2004, 3:117-124.
36. Inoue Y., et al. Comparison of subcutaneous and intraperitoneal injection of D-luciferin for in vivo bioluminescence imaging. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:771-779.
37. Baba S., et al. How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach. Mol. Imaging 2007, 6:315-322.
38. Keyaerts M., et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D-luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:999-1007.
39. Wang W., El-Deiry W.S. Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol. Ther. 2003, 2:196-202.
40. Zhao H., et al. Characterization of coelenterazine analogs for measurements of Renilla luciferase activity in live cells and living animals. Mol. Imaging 2004, 3:43-54.
41. Otto-Duessel M., et al. In vivo testing of Renilla luciferase substrate analogs in an orthotopic murine model of human glioblastoma. Mol. Imaging 2006, 5:57-64.
42. Kimura T., et al. Optimization of enzyme-substrate pairing for bioluminescence imaging of gene transfer using Renilla and Gaussia luciferases. J. Gene Med. 2010, 12:528-537.
43. Inouye S., Shimomura O. The use of Renilla luciferase, Oplophorus luciferase, and apoaequorin as bioluminescent reporter protein in the presence of coelenterazine analogues as substrate. Biochem. Biophys. Res. Commun. 1997, 233:349-353.
44. Tozer G.M. Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br. J. Radiol. 2003, 76:S23-S35.
45. Pichler A., et al. Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:1702-1707.
46. Zhang Y., et al. ABCG2/BCRP expression modulates D-luciferin based bioluminescence imaging. Cancer Res. 2007, 67:9389-9397.
47. Jeon Y.H., et al. Evaluation of the reversal of multidrug resistance by MDR1 ribonucleic acid interference in a human colon cancer model using a Renilla luciferase reporter gene and coelenterazine. Mol. Imaging 2010, 9:343-350.
48. Cecic I., et al. Oxygen sensitivity of reporter genes: implications for preclinical imaging of tumor hypoxia. Mol. Imaging 2007, 6:219-228.
49. Moriyama E.H., et al. The influence of hypoxia on bioluminescence in luciferase-transfected gliosarcoma tumor cells in vitro. Photochem. Photobiol. Sci. 2008, 7:675-680.
50. Bakhtiarova A., et al. Resveratrol inhibits firefly luciferase. Biochem. Biophys. Res. Commun. 2006, 351:481-484.
51. Rocha S., et al. The p53-inhibitor pifithrin-alpha inhibits firefly luciferase activity in vivo and in vitro. BMC Mol. Biol. 2003, 4:9.
52. Auld D.S., et al. Characterization of chemical libraries for luciferase inhibitory activity. J. Med. Chem. 2008, 51:2372-2386.
53. Ueda I. Effects of diethyl ether and halothane on firefly luciferin bioluminescence. Anesthesiology 1965, 26:603-606.
54. Franks N.P., Lieb W.R. Molecular and cellular mechanisms of general anesthesia. Nature 1994, 367:607-614.
55. Keyaerts M., et al. Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging. PLoS ONE 2012, 7:e30061.
56. Loening A.M., et al. Red-shifted Renilla reniformis luciferase variants for imaging in living subjects. Nat. Methods 2007, 4:641-643.
57. Shapiro E., et al. A set of multicolored Photinus pyralis luciferase mutants for in vivo bioluminescence applications. Protein Eng. Des. Sel. 2005, 18:581-587.
58. Zhao H., et al. Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. J. Biomed. Opt. 2005, 10:41210.
59. Virostko J., Jansen E.D. Validation of bioluminescent imaging techniques. Methods Mol. Biol. 2009, 574:15-23.
60. Virostko J., et al. Factors influencing quantification of in vivo bioluminescence imaging: application to assessment of pancreatic islet transplants. Mol. Imaging 2004, 3:333-342.
61. Colin M., et al. Haemoglobin interferes with the ex vivo luciferase luminescence assay: consequence for detection of luciferase reporter gene expression in vivo. Gene Ther. 2000, 7:1333-1336.
62. Curtis A., et al. Temporal variations of skin pigmentation in C57Bl/6 mice affect optical bioluminescence quantitation. Mol. Imaging Biol. 2011, 13:1114-1123.
63. Prescher J.A., Contag C.H. Guided by the light: visualizing biomolecular processes in living animals with bioluminescence. Curr. Opin. Chem. Biol. 2010, 14:80-89.
64. Close D.M., et al. Autonomous bioluminescent expression of the bacterial luciferase gene cassette (lux) in a mammalian cell line. PLoS ONE 2010, 5:e12441.
65. Stefan E., et al. Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16916-16921.
66. Zhang L.M., et al. Molecular imaging of Akt kinase activity. Nat. Med. 2007, 13:1114-1119.
67. Xu Y., et al. A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:151-156.
68. Xia Z., Rao J. Biosensing and imaging based on bioluminescence resonance energy transfer. Curr. Opin. Biotechnol. 2009, 20:37-44.
69. Dragulescu-Andrasi A., et al. Bioluminescence resonance energy transfer (BRET) imaging of protein-protein interactions within deep tissues of living subjects. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12060-12065.
70. Coppola J.M., et al. Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin. Cancer Res. 2008, 14:2492-2501.
71. Hickson J., et al. Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin. Cell Death Differ. 2010, 17:1003-1010.
72. Dragulescu-Andrasi A., et al. In vivo bioluminescence imaging of furin activity in breast cancer cells using bioluminogenic substrates. Bioconjug. Chem. 2009, 20:1660-1666.
73. Kong Y., et al. Whole-body imaging of infection using bioluminescence. Curr. Protoc. Microbiol. 2011, 21. 2C.4.1-2C.4.17.
74. Hsieh C.L., et al. A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. J. Mol. Endocrinol. 2005, 35:293-304.
75. Couillard-Despres S., et al. In vivo optical imaging of neurogenesis: watching new neurons in the intact brain. Mol. Imaging 2008, 7:28-34.